{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:36:16Z","timestamp":1753889776699,"version":"3.41.2"},"reference-count":16,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>We reported a case of multiple sclerosis (MS) with persistent symptomatic\nCOVID-19, which was complicated by new-appearing severe pneumonia 40 days after disease onset.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case presentation:<\/jats:title>\n<jats:p>A 38-year-old man with a history of multiple sclerosis referred to our hospital with\nfever, shaking chills, cough, and dyspnea. In his history, the patient had developed mild COVID-19\nfrom 40 days ago. After 7 days of disease onset, the COVID symptoms had been subsided partially,\nbut fatigue, myalgia, intermittent fever, and loss of taste and smell had been continued. In physical\nexaminations, his oral temperature was 39.4 \u00b0C. He had respiratory distress, and his blood oxygen\nsaturation on the room air was 90%. The spiral chest CT scan was performed, which revealed bilateral\nground-glass and alveolar opacities in favor of COVID-19 pneumonia. The result of the RT-PCR test\nfor SARS-COV-2 was reported positive subsequently. His current MS medication was rituximab and\nhe had received the last dose of rituximab two months before developing COVID-19. The patient was\nadmitted to the COVID ward and put on Remdesivir, subcutaneous interferon-beta1b, and dexamethasone.\nHe improved gradually and was discharged from the hospital with the favorable condition after\n10 days. This patient had a rare protracted disease course. We presumed that prolonged high degree\nfever (above 38 \u00b0C) in our patient is beyond the diagnosis of the post-COVID-19 syndrome and is\nmore compatible with persistent infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Although most immunocompromised patients effectively clear SARS-CoV-2 infection,\nthis case report highlights the risk of persistent infection associated with recurrence of the disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871526522666220128121855","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T11:59:35Z","timestamp":1643371175000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Case of Multiple Sclerosis with Protracted Course of COVID-19"],"prefix":"10.2174","volume":"22","author":[{"given":"Mehrdad","family":"Hasibi","sequence":"first","affiliation":[{"name":"Amir Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Asadollahi","sequence":"additional","affiliation":[{"name":"Loghman-Hakim Hospital, Shahid\nBeheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Asadollahi-Amin","sequence":"additional","affiliation":[{"name":"Amir Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.2020.19719","volume":"324","author":"Del Rio C.","year":"2020","unstructured":"Del Rio C.; Collins L.F.; Malani P.; Long-term health consequences of COVID-19. JAMA 2020,324(17),1723-1724","journal-title":"JAMA"},{"year":"2020","author":"Assaf G","key":"ref=2","unstructured":"Assaf G; Davis H; McCorkell L;   What does COVID-19 recovery\nactually look like? An analysis of the prolonged COVID-19\nsymptoms survey by Patient-Led Research Team. Patient Led Research\nfor COVID-19  2020"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.29.20164418","author":"Banda JM","year":"2020","unstructured":"Banda JM; Singh GV; Alser O; Long-term patient-reported\nsymptoms of COVID-19: An analysis of social media data. medRxiv 2020"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.05.20146886","author":"O\u2019Keefe JB","year":"2020","unstructured":"O\u2019Keefe JB; Cellai M; Characterization of prolonged COVID-19\nsymptoms and patient comorbidities in an outpatient telemedicine cohort.\nmedRxiv 2020"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","volume":"324","author":"Carf\u00ec A.","year":"2020","unstructured":"Carf\u00ec A.; Bernabei R.; Landi F.; Persistent symptoms in patients after acute COVID-19. JAMA 2020,324(6),603-605","journal-title":"JAMA"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"00542","DOI":"10.1183\/23120541.00542-2020","volume":"6","author":"Go\u00ebrtz Y.M.J.","year":"2020","unstructured":"Go\u00ebrtz Y.M.J.; Van Herck M.; Delbressine J.M.; Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res 2020,6(4),00542-02020","journal-title":"ERJ Open Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","volume":"26","author":"He X.","year":"2020","unstructured":"He X.; Lau E.H.; Wu P.; Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020,26,672-675","journal-title":"Nat Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.21037\/apm-20-996","volume":"10","author":"Wei L.","year":"2021","unstructured":"Wei L.; Liu B.; Zhao Y.; Chen Z.; Prolonged shedding of SARS-COV-2 in an elderly liver transplant patient infected by COVID-19: A case report. Ann Palliat Med 2021,10(6),7003-7007","journal-title":"Ann Palliat Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","volume":"183","author":"Avanzato V.A.","year":"2020","unstructured":"Avanzato V.A.; Matson M.J.; Seifert S.N.; Case study: Prolonged infectious SARS-COV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 2020,183(7),1901-1912.e9","journal-title":"Cell"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.3390\/ijerph17124279","volume":"17","author":"Lakhani H.V.","year":"2020","unstructured":"Lakhani H.V.; Pillai S.S.; Zehra M.; Sharma I.; Sodhi K.; Systematic review of clinical insights into novel coronavirus (CoVID-19) pandemic: Persisting challenges in U.S. rural population. Int J Environ Res Public Health 2020,17(12),4279","journal-title":"Int J Environ Res Public Health"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","volume":"383","author":"Aydillo Teresa","year":"2020","unstructured":"Aydillo Teresa; Ana S. Gonzalez\u2010Reiche; Sadaf Aslam; Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 2020,383(26),2586-2588","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-020-00968-1","volume":"13","author":"Lancman G.","year":"2020","unstructured":"Lancman G.; Mascarenhas J.; Bar-Natan M.; Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 2020,13(1),131","journal-title":"J Hematol Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40560-020-00453-4","volume":"8","author":"Huang I.","year":"2020","unstructured":"Huang I.; Pranata R.; Lymphopenia in severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis. J Intensive Care 2020,8,36","journal-title":"J Intensive Care"},{"key":"ref=14","first-page":"29","volume":"2","author":"Jason J.","year":"2009","unstructured":"Jason J.; Emer, Wolinsky Claire. 6.Rituximab: A review of dermatological applications. Clin Aesthet Dermatol 2009,2(5),29-37","journal-title":"Clin Aesthet Dermatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00296-020-04715-0","volume":"40","author":"Kow C.S.","year":"2020","unstructured":"Kow C.S.; Hasan S.S.; Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int 2020,40(12),2117-2118","journal-title":"Rheumatol Int"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218075","volume":"80","author":"Schulze-Koops H.","year":"2020","unstructured":"Schulze-Koops H.; Krueger K.; Vallbracht I.; Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2020,80(5)","journal-title":"Ann Rheum Dis"}],"container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871526522666220128121855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200652\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871526522666220128121855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T18:22:26Z","timestamp":1693160546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200652\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526522666220128121855","relation":{},"ISSN":["1871-5265"],"issn-type":[{"type":"print","value":"1871-5265"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e280122200652"}}